CClinicalTrials.gg
Status unknownNCT03444974MATRIX-AUpdated Apr 1, 2019

Addiction in Adolescence - Pathomechanisms and Treatment Evaluation

An interventional study of adapted treatment according to the MATRIX-A therapy in Substance Use Disorders and Adolescent Behavior, sponsored by Technische Universität Dresden. Status unknown at 1 site in Germany. Open to participants aged 12 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-01.

Sponsored by Technische Universität Dresden · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Non-randomized
Ages
12 Years to 17 Years
Sex
All
01

Study summary

This study aims to investigate the sociodemographic background as well as psychiatric comorbidities of adolescent substance users with substance use disorders. The study simultaneously evaluates biomarkers of stress and addiction, including long-term cortisol levels from hair samples and gene methylation in blood samples associated with substance use.

Our study also adapts, rolls out, and evaluates an evaluated multimodal treatment manual wich was originally intended for stimulant drug users (MATRIX). We adopt this manual to the needs and specifics of adolescents (MATRIX-A, A=adolescents) with substance use disorders of any substance, including cannabis, methamphetamine, and alcohol. Adolescents will receive group therapy sessions, individual therapy sessions, and medication if needed, while parents or professional caretaker will receive group sessions. Therapy outcomes will be examined in addition to parental distress and parenting skills.

Read the detailed description

As numbers of adolescent drug abuse have grown rapidly within the last couple of years, research on youth drug abuse and dependency has taken a new and vital role within the public healthcare system. For this reason, it is crucial to find new ways to effectively integrate adolescent patients into the health care system, as well as assign them to treatment options tailor made for the specific challenges and needs of this population. This study aims to investigate (a) sociodemographic background and psychiatric comorbidities in connection with adolescent substance abuse and dependence to enhance understanding of epidemiologic risk factors for developing drug dependency in adolescence, as well as benefit future treatment options.

It further aims to investigate (b) molecular and epigenetic mechanisms of addiction disorders in adolescents by analyzing methylation pattern, as well as proteome analysis of peripheral immune markers. The investigator's aim is a better understanding of the multimodal biological underpinnings of risk/resilience for addiction in youth on the molecular, cellular and circuit levels with a special focus on the changes within the stress and immune system in patients with addiction disorders and their family members.

Another research interest of this study concerns (c) adapting and evaluating new treatment options, tailor made for the adolescent population. For this reason the investigators aim to adapt, implement and evaluate a therapeutic program according to the MATRIX manual for the treatment of substance abuse, which consists of two group therapies for patients, as well as their parents (Evaluation time points: T0, T1, and T2).

Last, this study aims to (d) evaluate parental stress levels, parental communication skills and knowledge in connection with adolescent substance abuse.

02

Conditions studied

  • Substance Use Disorders
  • Adolescent Behavior

Keywords

  • drugs
  • youth
  • adolescence
  • abuse
  • dependence
  • Tetrahydrocannabinol (THC)
  • Methamphetamine (Crystal Meth)
  • Marihuana
  • comorbidity
  • treatment
  • etiopathology
  • sociodemographics
  • Saxony
  • MATRIX
  • Psychotherapy
03

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Adolescents:

Inclusion Criteria:

  • Age 12.00-17.99
  • Therapy / wait list group: current substance use disorder
  • Controls: no history of substance use disorders

Exclusion Criteria:

  • Preexisting neurological diseases
  • Diseases of or with involvement of the central nervous system
  • Intelligence quotient (IQ) \< 70
  • Diseases concerning the adrenal gland, pituitary gland or hypothalamus
  • Acute viral diseases during T0, T1, T2
  • Controls:

    • Drug intake modulating the central nervous system
    • Main psychiatric disorders
    • Current substance use

Parents:

Inclusion Criteria:

  • At least one child/protégé with problematic substance abuse
  • No current substance abuse on their own
  • At least one parent must be eligible to participate in the group

Exclusion Criteria:

  • Current substance abuse
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Active comparator
    Patient therapy group

    * Adolescents with substance use disorders * Receiving an adapted treatment according to the MATRIX-A therapy

    Other: adapted treatment according to the MATRIX-A therapy

  • Active comparator
    Parental therapy group

    * Parents of adolescents with substance use disorders * Receiving an adapted treatment according to the MATRIX-A therapy

    Other: adapted treatment according to the MATRIX-A therapy

  • No intervention
    Patient waiting list group

    * Adolescents with substance use disorders * On the waiting list for receiving a MATRIX-A therapy

  • No intervention
    Parental waiting list group

    * Parents of adolescents with substance use disorders * On the waiting list for receiving a MATRIX-A therapy

  • No intervention
    control group

    * Adolescents with no history of substance use disorders * no other intake of psychotropic substances such as psychotropic medication

Interventions

  • Otheradapted treatment according to the MATRIX-A therapy

    cognitive and behavioral treatment of drug abuse/dependency issues, as well as connected parameters

05

What researchers measure

Primary outcomes

  1. Aim 1: Sociodemographic background

    Sociodemographic background of adolescents with substance use disorders via self-constructed items: * age (in years) * gender (male/female) * highest education (primary school/ currently in high school/ dropped out of school/ finished compulsory school/ finished apprenticeship/ currently doing apprenticeship) * migration background (no/ yes \> asks for specification) * nationality (German/ other \> asks for specification) * relationship status (single/ married/ separated/ divorced/ widowed/ civil union/ domestic partnership/ other \> asks for specification)

    Time frame: T0

  2. Aim 2: Psychiatric comorbidities - MINI-KID

    Current psychiatric comorbidities according to Diagnostic and Statistic Manual of Mental Disorders, 5th Ed. (DSM-5) assessed via Mini International Neuropsychiatric Interview for Children and Adolescents (MINI KID), a structured diagnostic interview. Single interview questions rated (yes / no). DSM-5 diagnoses for past month (or other if specified) in accordance with MINI-KID scoring algorithms.

    Time frame: T0, T1, T2

  3. Aim 2: Change in substance use

    Changes in self-reported substance use between T0, T1, T2. Assessed via quantity and frequency questions for different substance categories.

    Time frame: T0, T1, T2

  4. Aim 3: Changes in biomarkers related to substance use disorders

    * cumulative stress: hair cortisol levels in a single hair sample. Measured in ng/ml. * epigenetic changes: methylation pattern in a single blood sample. Measured in %. * immunological changes: immune marker Interleukin-6 in a single blood sample. Measured in ng/ml.

    Time frame: T0, T1, T2

  5. Aim 4: Subjective therapy outcomes

    * Evaluation of possible therapy effects (e.g. knowledge, relapse prevention skills, emotions/affects, maintenance self-efficacy, motivation, stress tolerance) with 5-point Likert options (not at T0). * Substance use disorder severity assessed via Drug Use Disorders Identification Test (DUDIT). Measured in a test persons's scoring number on the DUDIT scale. Change from baseline DUDIT score to T1 and T2 DUDIT scores.

    Time frame: T0, T1, T2

  6. Aim 4: Objective therapy outcomes

    - objective: Abstinence / relapse based on random drug urine tests for illicit substance use during therapy sessions.

    Time frame: between T0 and T1

  7. Aim 5: Change in baseline parenting skills

    Assessment of parenting skills (communication skills) via descriptive self-reports. Change from T0 to T1. Measured in self-reported description of change.

    Time frame: T0, T1

  8. Aim 5: Change in baseline parental stress reports - ESF

    Change from self-reported baseline parent stress level to T1 anjd T2 parental stress levels. Assessed via a German questionnaire assessing the amount of parental stress (ESF). Stress factors within everyday parent life are being measured with help of 38 items, which are being scored on a 4-point scale that ranges from 0(disagree) to 3 (completely agree). All items can be assigned to 4 different areas of stress, being social support (7 items, total score 0-21 points), workload and restrictions (7 items, total score 0-21 points), social support (7 items, total score 0-21 points) and cooperative partnership (7 items, total score 0-21). High scores report high stress levels.

    Time frame: T0, T1, T2

Secondary outcomes

  1. Emotional, behavioral and social problems of adolescents - Self-Rating (YSR)

    Emotional, behavioral and social problems associated with adolescents with substance use disorders: Data collection of existence of emotional/behavioral/social problems with help of the Youth Self-Report (YSR). Measured in a person's scoring on 8 different scales (anxious/depressed, withdrawn/depressed, somatic complaints, social problems, thought problems, attention problems, rule-breaking behavior, aggressive behavior) as well as a total score.

    Time frame: Baseline data collection

  2. Emotional, behavioral and social problems of adolescents - Parental Rating (CBCL)

    Emotional, behavioral and social problems associated with adolescents with substance use disorders: Data collection of existence of emotional/behavioral/social problems with help of the Child Behavior Checklist (CBCL). Measured in a person's scoring on 8 different scales (anxious/depressed, withdrawn/depressed, somatic complaints, social problems, thought problems, attention problems, rule-breaking behavior, aggressive behavior) as well as a total score.

    Time frame: T0, T1, T2

  3. Adolescent depressivity - BDI-II

    Psychiatric comorbidities associated with adolescents with substance use disorders: Data collection with help of the Beck Depression Inventory (BDI-II). Measured in a test persons's scoring number on the scale.

    Time frame: T0, T1, T2

  4. Mental distress - Brief Symptom Checklist

    Psychiatric comorbidities associated with adolescents with substance use disorders: Data collection with help of the Brief Symptom Checklist (BSCL). Current amount of mental distress is measured in a person's numerical global severity index.

    Time frame: T0, T1, T2

  5. Adolescent satisfaction with life

    Psychiatric comorbidities associated with adolescents with substance use disorders: Data collection with help of the Satisfaction With Life Scale (SWLS). The scale is designed to measure global cognitive judgments of one's life satisfaction with help of 5 items using a 7-point scale that ranges from 7 strongly agree to 1 strongly disagree. Scoring benchmarks: extremely dissatisfied (5-9), dissatisfied (10-14), slightly dissatisfied (15-19), neutral (20), slightly satisfied (21-25), satisfied (26-30), extremely satisfied (31-35).

    Time frame: T0, T1, T2

06

Study locations

1 of 1 sites recruiting
  • Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital C.G.Carus
    Dresden, Saxony 01307, Germany
    Recruiting
07

References and documents

Publications

  • Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D, Iguchi M; Methamphetamine Treatment Project. Psychiatric symptoms in methamphetamine users. Am J Addict. 2004 Mar-Apr;13(2):181-90. doi: 10.1080/10550490490436055. PubMed 15204668 ↗
  • Warden D, Sanchez K, Greer T, Carmody T, Walker R, Dela Cruz A, Toups M, Rethorst C, Trivedi MH. Demographic and clinical characteristics of current comorbid psychiatric disorders in a randomized clinical trial for adults with stimulant use disorders. Psychiatry Res. 2016 Dec 30;246:136-141. doi: 10.1016/j.psychres.2016.09.007. Epub 2016 Sep 15. PubMed 27693866 ↗
  • Rawson RA, Marinelli-Casey P, Anglin MD, Dickow A, Frazier Y, Gallagher C, Galloway GP, Herrell J, Huber A, McCann MJ, Obert J, Pennell S, Reiber C, Vandersloot D, Zweben J; Methamphetamine Treatment Project Corporate Authors. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction. 2004 Jun;99(6):708-17. doi: 10.1111/j.1360-0443.2004.00707.x. PubMed 15139869 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03444974
Lead sponsor
Technische Universität Dresden
Responsible party
Sponsor
First posted
Feb 26, 2018
Start date
Aug 1, 2018
Primary completion
Feb 28, 2021 (estimated)
Completion
Dec 31, 2021 (estimated)
Last update
Apr 1, 2019

Study contacts

Sören Kuitunen-Paul, Dipl.-Psych.
Contact
soeren.kuitunen-paul@ukdd.de
+49 (0)351 458-7601
Yulia Golub, Dr.Dr.habil.
Contact
yulia.golub@ukdd.de
+49 (0)351 458-7601
Veit Roessner, Prof. Dr.
study director · Technische Universität Dresden, Universitätsklinikum C.G.C. Dresden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion